Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome

Retina

Volumn 29, Issue 10, 2009, Pages 1418-1423

  Ehrlich, Rita ^a   Ciulla, Thomas A ^b   Maturi, Raj ^b   Kheradiya, Nisha S ^a   Hrisomalos, Nick ^b   Shulman, Shiri ^c   Guess, Matthew G ^a   Coyle, Ellen ^b   Harris, Alon ^a  

^a INDIANA UNIVERSITY   (United States)

^b METHODIST HOSPITAL   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LASER COAGULATION; OCULAR HISTOPLASMOSIS; OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; DRUG ANTAGONISM; FEMALE; FUNGAL EYE INFECTION; HISTOPLASMOSIS; INJECTION; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDY; SYNDROME; TREATMENT OUTCOME; VITREOUS BODY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; EYE INFECTIONS, FUNGAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HISTOPLASMOSIS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; SYNDROME; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 73349132721     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181babdf1     Document Type: Article

References (30)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in younger patients. Ophthalmology 1996;103:1241-1244.
2. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med 2000;342:483-492.
3. Ciulla TA, Piper HC, Xiao M, Wheat LJ. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. Curr Opin Ophthalmol 2001;12:442-449.
4. Olk RJ, Burgess DB, McCormick PA. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology 1984;91:1592-1602.
5. Kleiner RC, Ratner CM, Enger C, Fine SL. Subfoveal neovascularization in the ocular histoplasmosis syndrome: A natural history study. Retina 1988;8:225-229.
6. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1987;105:1499-1507.
7. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
8. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355:1419-1431.
9. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114: 2190-2196.
10. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165. (Pubitemid 46202863)
11. Mandal S, Garg S, Venkatesh P, Mithal C, Vohra R, Mehrotra A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007;125:1487-1492. (Pubitemid 350106680)
12. Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-1186. (Pubitemid 350211522)
13. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1242-1257.
14. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Macular Photocoagulation Study Group. Arch Ophthalmol 1989;107:344-352.
15. Davidorf FH, Hoskins JC, Marsh MJ, et al; Submacular Surgery Trials Research Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. I. Ophthalmic finding from a randomized clinical trail: Submacular Surgery Trails (SST) Group H trail: SST Report no 9. Arch Ophthalmol 2004;122:1597-1611.
16. Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003;136:739-741.
17. Shah GK, Blinder KJ, Hariprasad SM, et al. Photodynamic therapy for juxtafoveal choroidal neovascularization due to ocular histoplasmosis syndrome. Retina 2005;25:26-32.
18. Liu JC, Boldt HC, Folk JC, Gehrs KM. Photodynamic therapy of subfoveal and juxtafoveal choroidal neovascularization in ocular histoplasmosis syndrome: A retrospective case series. Retina 2004;24:863-870.
19. Busquets MA, Shah GK, Wickens J, et al. Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina 2003;23:299-306.
20. Saperstein DA, Rosenfeld PJ, Bressler NM, et al; Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 2002;109:1499-1505.
21. Rosenfeld PJ, Saperstein DA, Bressler NM, et al; Verteporfin in Ocular Histoplasmosis Study Group. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled open label 2-year study. Ophthalmology 2004;111:1725-1733.
22. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Verteporfin therapy for CNV secondary to OHS. Ophthalmology 2006; 113:2371.e1- e3.
23. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 2005;89:147-150.
24. Rosenblatt BJ, Shah GK, Blinder K. Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization. Retina 2005;25:33-37. (Pubitemid 40250405)
25. Lam A, Lee HC, Ho AC, et al. Photodynamic therapy in young patients. Ophthalmic Surg Lasers Imaging 2006;37: 182-189.
26. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;118:327-336.
27. Lim JI, Flaxel CJ, LaBree L. Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease. Ann Acad Med Singapore 2006;35:198-202.
28. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135:343-350.
29. Adán A, Navarro M, Casaroli-Marano RP, Ortiz S, Molina JJ. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 2007;245:1873-1875.
30. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008;145:875-878.